secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001559053-24-000028
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena CMO Hideki Garren departs; Chad Swanson appointed Chief Development Officer
--------------------------------------------------------------------------------

- Hideki Garren, M.D., Ph.D., resigns as Chief Medical Officer effective Sept 27, 2024, to lead global product development at a large pharma.
- Chad Swanson, Ph.D., promoted to Chief Development Officer; will lead clinical development and medical functions.
- Swanson joined Prothena in Jan 2023 from Eisai, where he led the lecanemab program for early Alzheimer's disease.
- Prothena will initiate a search for a new Chief Medical Officer.
- Swanson will join the executive leadership team and report to CEO Gene Kinney.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000028/0001559053-24-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000028/prta-20240923.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer